Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2021

Feb 18, 2022

SELL
$100.76 - $138.36 $3.93 Million - $5.4 Million
-39,020 Closed
0 $0
Q3 2021

Nov 12, 2021

BUY
$132.37 - $176.78 $5.17 Million - $6.9 Million
39,020 New
39,020 $5.23 Million

Others Institutions Holding NTLA

About Intellia Therapeutics, Inc.


  • Ticker NTLA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,011,800
  • Market Cap $926M
  • Description
  • Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...
More about NTLA
Track This Portfolio

Track Castle Ark Alternatives, LLC Portfolio

Follow Castle Ark Alternatives, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Castle Ark Alternatives, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Castle Ark Alternatives, LLC with notifications on news.